Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma

Hee Hyun Park; Sea-Won Lee; Soo Yoon Sung; Byung Ock Choi

doi:10.3857/roj.2017.00374

Radiation Oncology Journal > Volume 35(3); 2017 > Article

Park, Lee, Sung, and Choi: Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma

Original Article

Clinical Investigation

Radiation Oncology Journal 2017; 35(3): 249-256.

Published online: September 29, 2017

DOI: https://doi.org/10.3857/roj.2017.00374

Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma

Hee Hyun Park, MD^*, Sea-Won Lee, MD^*, Soo Yoon Sung, MD, Byung Ock Choi, MD, PhD

Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence: Byung Ock Choi, MD, PhD, Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea.
Tel: +82-2-2258-1527, Fax: +82-2-2258-1532, E-mail: choibo67@catholic.ac.kr

^* Both authors contributed equally to this work.

Received July 18, 2017 Revised September 06, 2017 Accepted September 18, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

We retrospectively reviewed the results of radiotherapy for localized ocular adnexal MALT lymphoma (OAML) to investigate the risk factors of cataract.

Methods

Sixty-seven patients with stage IE OAML treated with radiotherapy at Seoul St. Mary’s Hospital from 2001 to 2016 were included. Median treatment dose was 30 Gy. Lens protection was done in 52 (76%) patients. Radiation therapy (RT) extent was as follows: superficial (82.1%), tumor mass (4.5%), and entire orbital socket (13.4%). The risk factors for symptomatic cataract were analyzed using the Cox proportional hazard model.

Results

Median follow-up time was 50.9 months (range, 1.9 to 149.4 months). All patients were alive at the time of analysis. There were 7 recurrences and there was no local recurrence. Median time to recurrence was 40.4 months. There were 14 cases of symptomatic cataract. Dose >30 Gy had hazard ratio of 3.47 for cataract (p = 0.026). Omitting lens protection showed hazard ratio of 4.10 (p = 0.008).

conclusions

RT achieves excellent local control of ocular MALT lymphoma. Consideration of RT-related factors such as lens protection and radiation dose at the stage of RT planning may reduce the risk of RT-induced cataract after radiotherapy.

Keywords: Marginal zone B-cell lymphoma, Radiotherapy, Cataract

Introduction

Extranodal mucosa-associated lymphoid tissue (MALT) lymphoma is the second most commonly diagnosed non-Hodgkin’s lymphoma in Korea [1]. Orbit is the most common site in which extranodal MALT lymphoma occurs [2]. Due to its radiosensitivity, radiotherapy alone achieves excellent tumor control especially in early localized disease, with 10-year relapse-free rate of 74% and 10-year overall survival of 89% [3]. Therefore, the treatment of choice for localized ocular adnexal MALT lymphoma is radiation therapy (RT). In this setting, cataract is the most commonly accounted serious late effect of radiotherapy [4]. This is a retrospective, single institutional study of radiotherapy for ocular adnexal MALT lymphoma to investigate treatment outcome and the risk factors of cataract.

Materials and Methods

1. Patients

Patients with biopsy-proven stage IE ocular adnexal MALT lymphoma (OAML) treated with definitive radiotherapy at Seoul St. Mary’s Hospital from November 2001 to March 2016 were included. Stage II–IV and patients who were treated with chemotherapy and patients with underlying cataract in the involved eye at initial work-up with slit lamp examination before RT were excluded. The primarily involved sites of ocular adnexal apparatus were divided into conjunctiva, eyelid, and lacrimal gland. Qualified hematologic pathologists diagnosed OAML according to the World Health Organization (WHO) criteria [5]. Seventy-six lesions from 67 patients were included. All procedures of this study were approved by the All procedures of this study were approved by the Institutional Review Board of Seoul St. Mary's Hospital (IRB No. KC16RISI0389).

The characteristics of the patients are summarized in Table 1. There was female preponderance (65.7%) in gender. The patients were median 42 years old (range, 18 to 75 years). Majority of the patients had unilateral involvement (86.6%). Bilateral involvement was observed in 9 patients (13.4%). The most commonly involved site was conjunctiva in 43 patients (64.2%). Eight patients had International Prognostic Index (IPI) score of 1 due to their age. Otherwise, IPI score for rest of the patients were 0. The most common initial clinical manifestation was appearance of palpable salmon-colored patchy lesion on the involved eye (n = 38) followed by conjunctival injection (n = 9), eye discomfort (n = 8), and orbital swelling (n = 5). No B symptoms were observed. The median time from clinical presentation to diagnosis was 4 months. Past histories related with cataract were found in 14 patients: diabetes mellitus (n = 5), hypertension (n = 7) and cataract in the contralateral eye (n = 2).

2. Staging

The initial staging evaluation of all patients with orbital MALT lymphoma included ophthalmologic examination, complete blood count, blood chemistry (with lactate dehydrogenase and liver function test), chest X-ray, contrast-enhanced computed tomography (CT) scan of the neck, chest, abdomen, and pelvis, CT or magnetic resonance imaging (MRI) of the orbit, positron emission tomography-CT (PET-CT), and bone marrow aspiration. The WHO classification was used for histopathologic diagnosis of MALT lymphoma [5]. Unilateral or bilateral ocular adnexal involvement without any other involvement was classified as Ann Arbor stage IE disease. Past histories related with cataract such as diabetes mellitus (DM), hypertension, and cataract in the contralateral eye were also taken.

3. Treatment

All patients were treated with definitive RT during weekdays, 5 days a week. The median treatment dose was 30 Gy (range, 22 to 45 Gy) and daily fraction size was 1.8–2.0 Gy. Radiation technique and dose were determined based on the location and extent of lesion. Electron beams (n = 57, energy 5–10 MeV) were given to superficial lesions such as conjunctiva and eyelid. Bolus of 0.5 cm or 1.0 cm thickness was applied if indicated. Majority of the radiation plans was single anterior field (n = 63). Deep-seated tumors were treated with 3D conformal plan (n = 3) and intensity-modulated radiotherapy (IMRT; n = 1). The RT extent was either superficial (n = 57), or covered tumor mass (n = 4) or entire orbital socket (n = 6). Target volume was defined as entire conjunctiva for conjunctival lesions and tumor mass for lacrimal glands. Entire orbital socket was treated in retrobulbar lesions. In order to reduce radiation exposure to lens, either contact lens shield (n = 32) or hanging block (n = 20) was used, provided the shielding did not reduce the target coverage [6]. Approximately 2 cm sized lens shield was used after application of anesthetic eye drop and lubricant. If the lens shield was too close that mass coverage would be compromised, hanging block was used. The lens shield and hanging block are shown in Fig. 1A–1C. Hanging block was positioned on the electron block so that the field light was completely blocked by communicating with the patient (Fig. 1D, 1E). The rate of lens protection was 42.3% before the year 2010 versus 57.7% after 2010 (p = 0.003). RT extent was superficial in 97.7% of conjunctival and 92.9% of eye lid lesions. 66.7% of lacrimal gland lesions were treated with an RT extent of tumor mass only. Entire orbital socket was included in the RT extent for retrobulbar lesions (p < 0.01). Majority of conjunctival and eyelid lesions were given ≤30 Gy while 66.7% of retrobulbar lesions were prescribed >30 Gy (p = 0.03). Lens protection was done in 84.1% of conjunctival, 85.7% of eyelid, 50% of retrobulbar, and 0% in lacrimal lesions (p < 0.01). The treatment characteristics are summarized in Table 2.

4. Follow-up

Treatment response was evaluated at 4–6 weeks after completion of RT by ophthalmologic examination, orbital CT, and MRI. The patients were followed up every 3 months for the first 2 years, and then every 6 months thereafter. Complete remission (CR) was defined as complete disappearance of involved lesion. Partial remission (PR) was defined as more than 50% reduction of pretreatment lesion size. Local recurrence was defined as reappearance of tumor after CR or increase in size of tumor after PR within the irradiated field during the follow-up. Overall survival (OS) and progression-free survival (PFS) were calculated from the first day of radiotherapy.

The adverse effects were assessed by ophthalmologist as well as radiation oncologist according to the Common Terminology Criteria of Adverse Effects version 4.0 (CTCAE 4.0) criteria [7]. Acute toxicity was defined as a toxicity developing within 3 months of beginning RT. Any toxicity observed afterwards was defined as late toxicity. All patients initially underwent ophthalmologic slit lamp examination by one ophthalmologist. Anterior segment including cataract was evaluated at each regular visit. Cataract was graded according to the CTCAE 4.0 criteria [7]. Grade 1 was defined as asymptomatic, diagnostically observable cataract. Grade 2 was defined as symptomatic cataract with moderately decreased visual acuity. Grade 3 cataract was defined as symptomatic cataract with markedly decreased visual acuity requiring surgery. Further ophthalmologic evaluation was performed by the ophthalmologist’s decision.

5. Statistics

Statistical analysis was performed with SPSS ver. 18.0 statistic software package (SPSS Inc., Chicago, IL, USA). The survival rates were estimated using the Kaplan-Meier method with log-rank test. The risk factors for cataract formation were analyzed with Cox proportional hazard model. The p-value of <0.05 was defined as statistically significant.

Results

1. Treatment outcome

Median follow-up time was 50.9 months (range, 1.9 to 149.4 months). All patients were alive with CR at the time of analysis. Six patients relapsed in the unirradiated contralateral eye and one patient had recurrence in the ipsilateral parotid gland. Median time to recurrence was 40.4 months (range, 8.6 to 72.2 months). The ocular recurrences were located at conjunctiva (n = 4), eyelid (n = 2), and lacrimal sac (n = 1). Among patients with recurrence, the female to male ratio was 1:1, and median age was 34 years (range, 18 to 57 years). All patients with contralateral eye recurrence were given radiotherapy with median dose of 27.6 Gy (range, 25.2 to 35.2 Gy). The patient with parotid recurrence at 8.6 months after completion of RT was treated with cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (CHOP) regimen for four cycles. All patients with recurrence were effectively salvaged and are alive with CR.

The PFS rate was 88.1% at 5 years. There was no difference the in 5-year PFS rates between ≤30 Gy and >30 Gy dose groups (p = 0.667). The 5-year PFS rates of patients with lens protection were 90.1% and patients without lens protection were 82.1%, respectively (p = 0.971). There was no statistically significant difference in PFS among different RT extent (superficial, tumor mass, and entire orbital socket).

2. Toxicity

The most common acute toxicity was periorbital dermatitis during or after radiotherapy (n =18). The incidence and types of late effects are summarized in Table 3. The most common late toxicity was xerophthalmia (n = 29). There were 29 episodes of Grade 2 late toxicity and 14 episodes of Grade 3 late toxicity. The most common Grade 3 late toxicity was cataract (n = 8), followed by ptosis (n = 3), xerophthalmia (n = 2), and nasolacrimal duct obstruction (n = 1). The total rate of cataract was 26.5% and median time to symptomatic cataract formation was 34.9 months (range, 14.4 to 58.2 months).

3. Risk factors for symptomatic cataract formation

The risk factors for symptomatic cataract were analyzed using the Cox proportional hazard model. Dose >30 Gy was associated with cataract formation with hazard ratio (HR) of 3.47 (p = 0.026). Omitting lens protection also showed a HR of 4.10 (p = 0.008). The results are summarized in Table 4.

The 5-year probability of cataract formation was 26% in the patients with lens protection and 63.3% in patients without lens protection, respectively (p = 0.004). Higher rate of cataract was observed in the ≥30 Gy group (≥30 Gy 46.7% vs. <30 Gy 13.5% at 5 years; p = 0.001). There was no statistically significant association between underlying risk factors for cataract such as DM, hypertension, and contralateral cataract and symptomatic cataract formation.

Discussion and Conclusion

The treatment of choice for OAML is radiotherapy. In early localized disease, radiotherapy alone achieves excellent outcome with reported 10-year relapse-free rate of 74% and 10-year overall survival of 89% [3]. After a median follow-up of 50.9 months, the PFS rate was 88.1% at 5 years in our data. There was no local recurrence and all patients were alive at the time of analysis. The treatment outcome was comparable to previous reports (Table 5).

Radiation-induced cataract is a deterministic effect. Thus, it develops if lens is exposed to radiation over a certain threshold dose, which is known as 2 Gy in single fraction and 5 to 8 Gy in fractionated therapy [8]. There are numerous reports on the radiotherapy of ocular lymphoma and RT-induced cataract in the literature. However, due to the rarity of the disease, most of them are retrospective studies from single institutions. Treatment outcome and cataract rates after radiotherapy in ocular MALT lymphoma patients are summarized in Table 5. Data including histology other than MALT lymphoma or patients who did not receive radiotherapy were excluded.

We assessed stage IE patients exclusively and delivered median dose of 30 Gy. Previous studies that included stage IE delivered median doses ranging from 25 Gy to 36 Gy [9-15]. The PFS rate of our data was 88.1% at 5 years, and the PFS rates of the studies mentioned above were 63.5%–92% [9-15]. The tumor outcome of this study was comparable to those of previous studies that only included stage IE patients. The total cataract rate of this study was 26.5%. The total rates of cataract after RT ranged from 4.2%–55.4% in the literature (Table 5) [6,9-20]. This wide range of cataract rates may be due to the variation in different endpoints of cataract grades, follow-up time, radiation dose, and other risk factors for cataract among studies.

Multiple studies repeatedly reported that lens protection was the most critical factor related to cataract, similar to our results. Lens protection was done in 10%–85.4% of the patients in previous studies, which may have been affected by tumor location or extent [6,9,11-15,17,19,20]. Lens protection resulted in lower rates of cataract formation (with lens protection 0%–27% vs. without lens protection 4%–55.9%) [11-14,19,20]. The difference in rates of cataract formation was statistically significant in our study (with lens protection 26% vs. without lens protection 63.3% at 5 years; p = 0.004) as in previous studies [11,12,14]. Most centers used lens shields directly placed on cornea and few institutions used hanging blocks. We used both the lens shields and hanging blocks accordingly depending on the tumor site to minimize radiation exposure to the lens and maximize the coverage of target.

In the literature, dose with higher rate of cataract formation ranged from 29.27–45 Gy. In our study, the dose with higher rate of cataract formation was 30 Gy (<30 Gy 13.5 % vs. ≥30 Gy 46.7%; p = 0.001). There was only one other study that identified the dose with higher rate of cataract formation, which was 36 Gy (<36 Gy 21.3 % vs. ≥36 Gy 58.8%; p = 0.0027) [14]. Nam et al. [15] demonstrated a statistically significant difference in cataract rates according to RT extent (entire orbit 58% vs. partial orbit 2%). Although higher rates of cataract were observed in more extensive RT in our data too, the difference was not statistically significant.

As discussed above, the risk factors such as lens protection, radiation dose, and RT extent are crucial in cataract formation after radiotherapy. A commonly known risk factor for radiation-nonrelated cataract is age and this entity of cataract is usually diagnosed at the seventh decade of life [21,22]. The median age of patients who had cataract after radiotherapy in this study was 41 and age was not a statistically significant risk factor. Other risk factors of radiation-nonrelated cataract such as DM or contralateral cataract had no significant association with RT-induced cataractogenesis according to our data. Because the pathogenesis of RT-induced cataract is different from radiation-nonrelated cataract, main factors associated with cataract after ocular RT were RT-related factors [4]. Since these factors are modifiable, consideration of these factors may allow a chance for us to reduce the risk of cataract at the stage of radiotherapy planning. This is possible because there was no difference in tumor outcome according to dose, lens protection, and RT extent. In addition, recent guidelines recommend lower doses (24–25 Gy) and even ultralow-doses have been tried [23,24].

We analyzed a homogeneous population of stage IE patients. To evaluate the RT effect on cataract alone, patients treated with chemotherapy and underlying cataract in the involved eye were excluded. We especially emphasized on cataract and weighed the possible general risks for cataract formation such as age and underlying disease.

Considering the de-escalating trend of recently recommended RT doses (24–25 Gy), the limitation of this study is the relatively higher RT dose (median, 30 Gy). Thus, further inclusion of patients treated with lower doses is necessary. Although the follow-up time in our study was 50 months, which exceeds the time to RT-induced cataract in the literature of median 36 months (range, 8 to 56 months) after beginning RT, our data still needs longer follow-up for maturation of results [6,9,13-16]. Only few patients received IMRT in this study. IMRT may be considered in the future for patients with retrobulbar lesions, where it is difficult to spare lens with eye shield or hanging block [25].

In summary, RT is essential in the treatment of ocular MALT lymphoma and achieves excellent treatment outcome. Consideration of RT-related factors such as lens protection and RT dose may reduce the risk of radiation-induced cataract after radiotherapy of ocular MALT lymphoma.

Notes

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Fig. 1.

Lens shield (A, B) and hanging block (C) used for lens protection. Application of hanging block from inferior view (D) and superior view (E) is shown.

Table 1.

Patients' characteristics (n = 67)

Characteristic	Value
Gender
Male	23 (34.3)
Female	44 (65.7)
Age (yr)	42 (18-75)
≤50	47 (70.1)
>50	20 (29.9)
Laterality
Unilateral	58 (86.6)
Right	28 (41.8)
Left	30 (44.8)
Both	9 (13.4)
Involved site
Conjunctiva	43 (64.2)
Eyelid	15 (22.4)
Lacrimal gland	3 (4.5)
Retrobulbar	6 (9.0)
Past history
Diabetes mellitus	5 (7.5)
Hypertension	7 (10.4)
Contralateral cataract	2 (2.9)

Values are presented as number (%) or median (range).

Table 2.

Treatment characteristics (n = 67)

	Value
Radiation dose (Gy)	30 (22–45)
≤30	43 (64.2)
>30	24 (35.8)
Energy (MV or MeV)
≤6	23 (34.3)
>6	44 (65.7)
Beam type and energy (MV or MeV)
Photon	10 (14.9)
≤6	7 (10.4)
>6	3 (4.5)
Electron	57 (85.1)
≤6	16 (23.9)
>6	41 (61.2)
Block type
Lens protection (+)	52 (77.6)
Hanging block	20 (29.9)
Lens shield	32 (47.8)
Lens protection (-)	15 (22.4)
Simulation
2D	28 (41.8)
3D	39 (58.2)
Plan
Anterior single field	63 (94.0)
Conformal	3 (4.4)
IMRT	2 (2.9)
RT extent
Superficial	57 (85.1)
Tumor mass	4 (6.0)
Entire orbital socket	6 (9.0)

Values are presented as median (range) or number (%).

IMRT, intensity-modulated radiotherapy.

Table 3.

Late toxicities

Late toxicities	Grade 1	Grade 2	Grade 3	Total
Cataract	4 (5.9)	6 (8.8)	8 (11.8)	18 (26.5)
Xerophthalmia	13 (19.1)	14 (20.6)	2 (2.9)	29 (42.6)
Blepharitis	5 (7.3)	5 (7.4)	-	10 (14.7)
Retinopathy	2 (2.9)	1 (1.4)	-	3 (4.4)
Nasolacrimal duct obstruction	1 (1.5)	-	1 (1.5)	2 (2.9)
Ptosis	4 (5.9)	3 (4.4)	3 (4.4)	10 (14.7)
Total	29 (43.3)	29 (43.3)	14 (20.9)

Values are presented as number (%).

Table 4.

Risk factors for symptomatic cataract using Cox proportional hazard model

	HR (95% CI)	p-value
Age (yr)		0.369
≤50	1
>50	2.08 (0.42–10.27)
Dose (Gy)
≤30	1	0.026
>30	3.47 (1.16–10.35)
Lens protection		0.008
Yes	1
No	4.10 (1.44–11.70)
RT extent		0.649
Superficial	1
Entire orbital socket	1.14 (0.25–5.11)

HR, hazard ratio; CI, confidence interval.

Table 5.

Treatment outcome and cataract rates after radiotherapy of ocular MALT lymphoma

	n		Radiotherapy (RT)				Treatment outcome						Cataract rate
	n	Median follow-up time	Median dose (Gy)	Dose range (Gy)	Dose group (Gy)	Lens protection (%)	CR (%)	Local PFS (%)	PFS (%)	CSS (%)	OS (%)	Total (%)	Cataract Grade ≥	According to dose group (%)	According to lens protection (%)	According to RT extent (%)
Hata et al. [6]	30	35 mo	30	28.8-45.8	30-36	10	100	100	96	N/R	100	10	2	N/R	N/R	N/R
Hata et al. [6]	30	35 mo	30	28.8-45.8	30-36	10	100	5-yr	5-yr	N/R	5-yr	10	2	N/R	N/R	N/R
Ejima et al. [9]	42	48 mo	30.6	30-50	36	81	84	100	77	100	97	32	3	N/R	N/R	N/R
Ejima et al. [9]	42	48 mo	30.6	30-50	36	81	84	5-yr	5-yr	5-yr	5-yr	32	3	N/R	N/R	N/R
Suh et al. [16]	48	70 mo	30.6	5.4-30.6	N/R	Yes (% N/R)	88.5	93.8	93.1	97.9	86.9	4.2	3	N/R	N/R	N/R
Suh et al. [16]	48	70 mo	30.6	5.4-30.6	N/R	Yes (% N/R)	88.5	10-yr	10-yr	10-yr	10-yr	10-yr	3	N/R	N/R	N/R
Monzen and Hasebe [17]	14	47 mo	40	30-54	>40	50	100	100	100	N/R	N/R	21.4	3	N/R	N/R	N/R
Lee et al. [18]	29	21 mo	30.6	30.6-45	45	N/R	100	100	97	N/R	86	6.9	N/R	N/R	N/R	N/R
Platt et al. [10]	47	27 mo	25.2	20-36	29.27	N/R	N/R	100	N/R	N/R	N/R	27	N/R	N/R	N/R	N/R
Harada et al. [11]	86	9 yr	30	30-46	N/R	45	N/R	98.7	N/R	N/R	93.5	46.2	2	N/R	Yes: 27.4	N/R
								10-yr			10-yr				No: 50.9
															5-yr
															(p = 0.037)
Goda et al. [12]	89	5.9 yr	25	25-30	N/R	57	99	91	63.5	95.7	91.3	24.7	1	N/R	Yes: 15	N/R
									7-yr	7-yr	7-yr				No: 41
															7-yr
															G3
															(p = 0.003)
Tran et al. [19]	24	41 mo	24	24-25.2	N/R	19	100	100	90	N/R	100	41.7	3	N/R	Yes: 0	N/R
Tran et al. [19]	24	41 mo	24	24-25.2	N/R	19	100	5-yr	5-yr	N/R	5-yr	41.7	3	N/R	No: 45.5	N/R
Uno et al. [13]	50	46 mo	36	20-46	40	22	52	90	88	98	91	12	2	N/R	Yes: 0	N/R
Uno et al. [13]	50	46 mo	36	20-46	40	22	52	90	88	98	5-yr	12	2	N/R	No: 15.4	N/R
Ohga et al. [20]	53	3.9 yr	24	24-30	N/R	20.8	39.6	98.1	91.5	N/R	100	26.4	2	N/R	Yes: 9.1	N/R
Ohga et al. [20]	53	3.9 yr	24	24-30	N/R	20.8	39.6	98.1	5-yr	N/R	5-yr	26.4	2	N/R	No: 23.8	N/R
Hashimoto et al. [14]	78	66 mo	30.6	30-50	36	85.4	N/R	100	88.5	N/R	98.1	29.5	3	<36 Gy: 21.3	Yes : 9.1	N/R
											5-yr			≥36 Gy: 58.8	No: 55.9
														G3	G3
														(p = 0.0027)	(p < 0.001)
Nam et al. [15]	66	4 mo	30	20-45	N/R	49	64	95.4	92	N/R	96.4	16.3	2	N/R	N/R	Entire orbit: 58
								5-yr	5-yr		5-yr					Partial orbit: 2
								5-yr	5-yr		5-yr					(p < 0.001)
Present study	68	50.9 mo	30	23.4-63	30	77.6	100	100	88.1	100	100	26.5	2	<30 Gy: 25.4	Yes: 26	Conjunctiva: 33.8
								5-yr	5-yr	5-yr	5-yr			≥30 Gy: 52.5	No: 63.3	Retrobulbar mass: 50
														G ≥ 2	G ≥ 2	Entire orbital socket: 40
														5-yr	5-yr	5-yr
														(p = 0.001)	(p = 0.004)	(p = 0.691)

CR, complete remission; PFS, progression-free survival; CSS, cause-specific survival; OS, overall survival; RT, radiation therapy; N/R, not reported.

References

1. Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol 2011;45:254–60.

2. White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma: a clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology 1995;102:1994–2006.

3. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815–24.

4. Ferrufino-Ponce ZK, Henderson BA. Radiotherapy and cataract formation. Semin Ophthalmol 2006;21:171–80.

5. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008.

6. Hata M, Omura M, Koike I, et al. Treatment effects and sequelae of radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma. Int J Radiat Oncol Biol Phys 2011;81:1387–93.

7. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Washington, DC: National Institutes of Health, National Cancer Institute; 2009.

8. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.

9. Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosaassociated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol 2006;78:6–9.

10. Platt S, Al Zahrani Y, Singh N, Hill B, Cherian S, Singh AD. Extranodal marginal zone lymphoma of ocular adnexa: outcomes following radiation therapy. Ocul Oncol Pathol 2017;3:181–7.

11. Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys 2014;88:650–4.

12. Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosaassociated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011;81:e659–66.

13. Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa. Cancer 2003;98:865–71.

14. Hashimoto N, Sasaki R, Nishimura H, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:1509–14.

15. Nam H, Ahn YC, Kim YD, Ko Y, Kim WS. Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. Radiother Oncol 2009;90:236–41.

16. Suh CO, Shim SJ, Lee SW, Yang WI, Lee SY, Hahn JS. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 2006;65:228–33.

17. Monzen Y, Hasebe H. Radiotherapy for localized orbital mucosa-associated lymphoid tissue lymphoma. Ophthalmologica 2007;221:233–7.

18. Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 2005;84:13–8.

19. Tran KH, Campbell BA, Fua T, et al. Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma 2013;54:491–6.

20. Ohga S, Nakamura K, Shioyama Y, et al. Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Anticancer Res 2013;33:5575–8.

21. Leske MC, Chylack LT Jr, Wu SY. The lens opacities casecontrol study: risk factors for cataract. Arch Ophthalmol 1991;109:244–51.

22. Javitt JC, Wang F, West SK. Blindness due to cataract: epidemiology and prevention. Annu Rev Public Health 1996;17:159–77.

23. Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:11–31.

24. Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 2013;86:930–5.

25. Eng T, Ha CS. Image-guided radiation therapy in lymphoma management. Radiat Oncol J 2015;33:161–71.